EGFR and oropharyngeal carcinoma: “Entropy” has been used for prognostic prediction in patients with high-risk oropharynx carcinoma after chemoradiation, in lung cancer patients after EGFR tyrosine kinase inhibitor treatment, and has been linked to treatment failure in metastatic colorectal cancer [36,58,59].